Shots:

• The KFDA has approved Celltrion’s Remsima SC for RA while the company is planning to seek approval for IBD within the year through the change permit procedure and is expected to be available to the Korean patients following the completion of the permit for the addition of IBD indications
• Additionally- Celltrion has filed an application for a Remsima SC in Canada to enter the NA and plans to supply it throughout Canada via Celltrion's direct sales network. The company is expecting to launch the therapy in the US in 2020 and currently being evaluated in P-III study
• Remsima SC is the world’s first SC biosimilar referencing Janssen’s Remicade (infliximab) and has received EMA’s approval in Nov’2019

Click here ­to­ read full press release/ article | Ref: Celltrion | Image: Celltrion